References
- Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352: 1112–1120
- Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005; 28: 205–214
- Kolecki P. Venlafaxine induced serotonin syndrome occurring after abstinence from phenelzine for more than two weeks. J Toxicol Clin Toxicol 1997; 35: 211–212
- Brubacher JR. Treating the serotonin syndrome—antidote or support?. J Toxicol Clin Toxicol 1997; 35: 213–214
- Isbister GK, Hackett LP, Dawson AH, Whyte IM, Smith AJ. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol 2003; 56: 441–450
- Bramness JG, Morland J, Sorlid HK, Rudberg N, Jacobsen D. Carisoprodol intoxications and serotonergic features. Clin Toxicol 2005; 43: 39–45
- Nisijima K. Abnormal monoamine metabolism in cerebrospinal fluid in a case of serotonin syndrome. J Clin Psychopharmacol 2000; 20: 107–108
- Jaiswal S, Coombs RC, Isbister GK. Paroxetine withdrawal in a neonate with historical and laboratory confirmation. Eur J Pediatr 2003; 162: 723–724
- Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancyon serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60: 720–726
- Dingemanse J, Wallnofer A, Gieschke R, Guentert T, Amrein R. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the “serotonin syndrome”. Clin Pharmacol Ther 1998; 63: 403–413
- Cohen ML, Brody TM. 5-Hydroxytryptamine (Serotonin) and therapeutic agents that modulate serotonergic neurotransmition. Human pharmacology: molecular to clinical 3rd, TM Brody, J Larner, KP Minneman. St. Luis, Mosby-Year Book. 1998; 157–167